Clinical Trial Update: Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating DVS-233 for Major Depressive Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DVS-233

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED